• Finance Tax Investment

Covington Advises Arecor Therapeutics on AIM IPO

LONDON, June 17, 2021 – Covington advised Arecor Therapeutics plc on the admission of its shares to trading on the AIM market of the London Stock Exchange. The IPO raised gross proceeds of £20 million through an oversubscribed placing of ordinary shares giving the company a market capitalisation of approximately £62.5 million.

Iksuda Therapeutics closes $47 million financing round

Funding to accelerate clinical progression of Iksuda’s pipeline of new generation of antibody drug conjugates, targeting tumours with high unmet need Investment round led by Korean-based Mirae Asset Capital and Celltrion

Fieldfisher advises on £20 million fundraising for Diurnal Group

Fieldfisher's top ranked equity capital markets team has advised Panmure Gordon as sole broker on an oversubscribed fundraising for AIM-listed Diurnal Group plc, a specialist pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases.

Magdalen College seeks Strategic Partner to accelerate development of The Oxford Science Park

Oxford, UK, May 10 2021 – Magdalen College Oxford, owner of The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies, has announced that it is seeking a strategic partner with which to accelerate development of the Park.

Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets

Financing includes leading life-science investors Gilde Healthcare, Forbion, Novartis Venture Fund and Eli Lilly and Company

THE EPICENTRE OF THE DRUG INDUSTRY: HOW CROS’ BREADTH, TALENT, DIVERSITY AND EXPERTISE SUPPORTED UNPRECEDENTED SECTOR GROWTH TO BECOME THE BACKBONE OF BIOPHARMA

In recent years (CROs) have become the backbone of pharma and biotech research and development (R&D), the go-to source for in-depth know-how and niche expertise no longer available within such organisations. In recent years, the CRO sector has boomed. Despite being squeezed hard by COVID-19, according to new analysis out by Frost and Sullivan, the global market should still grow to $63.83 billion by 2024 from $43.03 billion in 2019, at a compound annual growth rate of 8.2%.

BIA analysis of 2021 Budget

The Chancellor has said that business support measures such as Furlough will continue, and more money has been made available to vaccine programmes. But alongside these measures to mitigate the impact of the pandemic, there was a promise of more investment in science and tech scale-ups, improvements to R&D tax credits to incentivise cutting edge science to be conducted in the UK, and rule changes to make it easier to list on the London Stock Exchange.

Fieldfisher Life Sciences sector group advised on £370 million of ECM transactions in 2020

Fieldfisher’s Band 1 ranked equity capital markets team advised on approximately £370 million worth of deals within the life sciences and healthcare sector last year.

Fieldfisher advises Panmure Gordon on fundraising for Diurnal Group Plc of up to £10m

We're delighted to announce that Fieldfisher's leading equity capital markets team represented Panmure Gorden (UK) Limited on the oversubscribed fundraising for Diurnal Group Plc of up to £10m.

Fieldfisher advises Synairgen plc on fundraising of up to £87 million to support Phase III trials of its potential COVID-19 treatment

European law firm Fieldfisher has advised AIM-quoted Synairgen plc, a leading respiratory disease drug discovery company based in Southampton, on its £87 million fundraising to begin the Phase III trial for a potential inhaled treatment for COVID-19